Copyright
©The Author(s) 2025.
World J Gastrointest Oncol. Apr 15, 2025; 17(4): 104253
Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.104253
Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.104253
Figure 1 Analysis of SHOX2, RASSF1A, SEPTIN9, and HOXA9 gene expression in normal tissue (n = 9) and cholangiocarcinoma tissue (n = 36) from previously reported genome data.
A-D: SHOX2, RASSF1A, SEPTIN9 and HOXA9 gene expression was upregulated in cholangiocarcinoma (CCA) tissue (n = 36); E-H: Beta values ranging from 0 (unmethylated) to 1 (fully methylated) indicate the DNA methylation levels of the SHOX2, RASSF1A, SEPTIN9 and HOXA9 promoters in normal tissue (n = 9) and CCA tissue (n = 36). CCA: Cholangiocarcinoma.
- Citation: Yu J, Liu QC, Lu SY, Wang S, Zhang H. Detecting plasma SHOX2, HOXA9, SEPTIN9, and RASSF1A methylation and circulating cancer cells for cholangiocarcinoma clinical diagnosis and monitoring. World J Gastrointest Oncol 2025; 17(4): 104253
- URL: https://www.wjgnet.com/1948-5204/full/v17/i4/104253.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v17.i4.104253